X

Trial Profile

Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vildagliptin (Primary) ; Pioglitazone
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

04 May 2012 The actual start date for the extension study is now July 2004 as reported by ClinicalTrials.gov. (Extension trial: NCT00138593)
04 May 2012 Status of extension study is completed as reported by ClinicalTrials.gov. (Extension trial: NCT00138593)
04 May 2012 The actual end date for the extension study is now Jul 2006 as reported by ClinicalTrials.gov. (Extension trial: NCT00138593)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com